- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- ADHD Group Visits, ADHD Group Visits plus Online Discussion Portal, Computer Decision Support
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 721–744
of 862
matching trials from the live ClinicalTrials.gov search.
- Conditions
- ADHD
- Interventions
- ADHD Therapy, Control Therapy
- Device
- Lead sponsor
- Lumos Labs, Inc.
- Industry
- Eligibility
- 22 Years to 55 Years
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Garden Grove, California • Sacramento, California + 10 more
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- ABT-089, placebo
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Bradenton, Florida • Jacksonville, Florida + 10 more
- Conditions
- ADHD
- Interventions
- Fidget ball
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Group-based behavior therapy, Stimulant medication therapy, Community-based psychosocial treatment
- Behavioral · Drug
- Lead sponsor
- Florida International University
- Other
- Eligibility
- 7 Years to 11 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- ADHD
- Interventions
- Vayarin, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Mindfulness-Based ADHD Treatment for Children, Goal-Standard Medication (Treatment as Usual)
- Behavioral · Biological
- Lead sponsor
- Yale University
- Other
- Eligibility
- 7 Years to 13 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- TC-5619-238 5mg, TC-5619-238 25mg, Placebo
- Drug
- Lead sponsor
- Targacept Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 14
- States / cities
- Beverly Hills, California • National City, California • Colorado Springs, Colorado + 9 more
- Conditions
- ADHD, Autism Spectrum Disorder
- Interventions
- Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
- Drug
- Lead sponsor
- Daniel Coury
- Other
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 11
- States / cities
- Irvine, California • Los Angeles, California • Portland, Maine + 8 more
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- CTN SR, Matching placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Newport Beach, California • Bradenton, Florida • Maitland, Florida + 1 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Brain Training (Active), Brain Training (Passive), Brain Training (Active or Passive)
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Childhood Disruptive Behavior Disorders, Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder, Parent-Child Interactions
- Interventions
- Triple P--Positive Parenting Program
- Behavioral
- Lead sponsor
- University of South Carolina
- Other
- Eligibility
- 3 Years to 7 Years
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 2
- States / cities
- Eugene, Oregon • Columbia, South Carolina
- Conditions
- Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders, Bipolar Disorder
- Interventions
- risperidone, olanzapine, aripiprazole
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- ADHD Collaborative
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Attention-deficit Hyperactivity
- Interventions
- Pharmacist Care, Primary Care Physician Care
- Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- ADHD
- Interventions
- Solriamfetol Dose A, Solriamfetol Dose B, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 28
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 25 more
- Conditions
- ADHD
- Interventions
- Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release, Dexmethylphenidate 50 mg Tablet
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Transcranial Direct Current Stimulation
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Occupational Therapy Intervention for Women with ADHD
- Behavioral
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 21 Years to 55 Years · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Attention-Deficit/Hyperactivity Disorder, ADHD
- Interventions
- ABT-894, atomoxetine, placebo
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 22
- States / cities
- San Francisco, California • Wildomar, California • Orlando, Florida + 19 more
- Conditions
- ADHD
- Interventions
- Nicotine, Placebo
- Drug · Other
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Attention-Deficit/Hyperactivity Disorder, ADHD
- Interventions
- TD-9855, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 17
- States / cities
- Bradenton, Florida • Jacksonville, Florida • Maitland, Florida + 13 more
- Conditions
- Attention Deficit Disorder
- Interventions
- Not listed
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
- Interventions
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 0 Years to 20 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more